The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Budzinskaya M.V.

Krasnov Research Institute of Eye Diseases

Durzhinskaya M.H.

Research Institute of Eye Diseases

Differential diagnosis of hydroxychloroquine-induced retinal damage

Authors:

Budzinskaya M.V., Durzhinskaya M.H.

More about the authors

Journal: Russian Annals of Ophthalmology. 2020;136(4): 265‑271

DOI: 10.17116/oftalma2020136042265

Read: 3061 times

Download PDF (RU)
Contact the author
Table of contents

DIFFERENTIAL DIAGNOSIS OF HYDROXYCHLOROQUINE-INDUCED RETINAL DAMAGE
DIFFERENTIAL DIAGNOSIS OF HYDROXYCHLOROQUINE-INDUCED RETINAL DAMAGE

To cite this article:

Budzinskaya MV, Durzhinskaya MH. Differential diagnosis of hydroxychloroquine-induced retinal damage. Russian Annals of Ophthalmology. 2020;136(4):265‑271. (In Russ.)
https://doi.org/10.17116/oftalma2020136042265

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Coronavirus infection is currently en extremely relevant scientific topic due to the emergence of a new serotype that causes a condition identified as Severe Acute Respiratory Syndrome (SARS)-COV-2. Chloroquine and hydroxychloroquine have a long history of use against other infectious diseases, they are available and inexpensive, so the possibility of using them in vivo and in vitro to suppress the infectious agent was examined. Despite the noted therapeutic potential of these drugs, it was necessary to take into account the toxicological aspects that dictate the importance of rational use of 4-aminoquinoline derivatives. This review analyzes literature on the development patterns of hydroxychloroquine retinopathy, basic principles of diagnosis and differentiation of this condition from other types of retinal pathology.

Keywords:

coronavirus
hydroxychloroquine
toxic retinopathy

Authors:

Budzinskaya M.V.

Krasnov Research Institute of Eye Diseases

Durzhinskaya M.H.

Research Institute of Eye Diseases

Received:

26.05.2020

Accepted:

17.06.2020

Close metadata

References:

  1. Jakhar D, Kaur I. Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus. Nature Medicine. 2020;26(5):632.  https://doi.org/10.1038/s41591-020-0853-0
  2. Sinha N, Balayla G. Hydroxychloroquine and covid-19. Postgraduate Medical Journal. 2020;137785. https://doi.org/10.1136/postgradmedj-2020-137785
  3. Yao X, Ye F, Zhang M. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2020; ciaa237. https://doi.org/10.1093/cid/ciaa237
  4. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. 2020;30(3):269‐271.  https://doi.org/10.1038/s41422-020-0282-0
  5. Biot C, Daher W, Chavain N, Fandeur T, Khalife J, Dive D, De Clercq E. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. Journal of Medicinal Chemistry. 2006;49(9):2845‐2849. https://doi.org/10.1021/jm0601856
  6. Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert Consensus on Chloroquine Phosphate for the Treatment of Novel Coronavirus Pneumonia. Zhonghua jie he he hu xi za zhi: Chinese journal of tuberculosis and respiratory diseases. 2020;43(3):185-188.  https://doi.org/10.3760/cma.j.issn.1001-0939.2020.03.009
  7. Potential Antiviral Drugs under Evaluation for the Treatment of COVID-19. Accessed March 12, 2020. https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/
  8. US Food and Drug Administration. Fact sheet for health care providers emergency use authorization (EUA) of hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of COVID-19 in certain hospitalized patients. April 27, 2020. Accessed March 28, 2020. https://www.fda.gov/media/136537/download
  9. US Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19): Information for Clinicians on Therapeutic Options for COVID-19 Patients. Accessed March 26, 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html
  10. Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, Ling Y, Huang D, Song S, Zhang D, Qian Z, Li T, Shen Y, Lu H. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). Journal of Zhejiang University. Medical sciences. 2020;49(2):215-221.  https://doi.org/10.3785/j.issn.1008- 9292.2020.03.03
  11. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of Critical Care. 2020;57:279-283.  https://doi.org/10.1016/ j.jcrc.2020.03.005
  12. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents. 2020;20:105949. https://doi.org/10.1016/jantimicag.2020.105949
  13. Avdeev SN. Vremennye metodicheskie rekomendacii. Lekarstvennaja terapija ostryh respiratornyh virusnyh infekci (ORVI) v ambulatornoj praktike v period jepidemii COVID-19. Accessed 16.04.2020. (In Russ.). https://static0.rosminzdrav.ru/system/attachments/attaches/000/050/033/original/RESP_REC_V2.pdf
  14. Shroyer NF, Lewis RA, Lupski JR. Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: Is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease? American Journal of Ophthalmology. 2001;131(6):761-766.  https://doi.org/10.1016/s0002-9394(01)00838-8
  15. Lee Y, Vinayagamoorthy N, Han K, Kwok SK, Ju JH, Park KS. Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis and Rheumatology. 2016;68(1):184-90.  https://doi.org/10.1002/art.39402
  16. Grassmann F, Bergholz R, Mändl J, Jägle H, Ruether K, Weber BH. Common synonymous variants in ABCA4 are protective for chloroquine induced maculopathy (toxic maculopathy). BMC Ophthalmology. 2015;6(15):18.  https://doi.org/10.1186/s12886-015-0008-0
  17. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmology. 2014;132(12):1453-1460. https://doi.org/10.1001/jamaophthalmol.2014.3459
  18. Tanaka M, Takashina H, Tsutsumi S. Comparative assessment of ocular tissue distribution of drug-related radioactivity after chronic oral administration of C14-levofloxacin and C14-chloroquine in pigmented rats. Journal of Pharmacy and Pharmacology. 2004;56(8):977-983.  https://doi.org/10.1211/0022357043932
  19. Marmor M, Kellner U, Lai TY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2016;123(6):1386-1394. https://doi.org/0.1016/j.ophtha.2016.01.058
  20. Pasaoglu I, Onmez FE. Macular toxicity after short-term hydroxychloroquine therapy. Indian Journal of Ophthalmology. 2019;67(2):289-292.  https://doi.org/10.4103/ijo.IJO_732_18
  21. Hernandez Bel L, Monferrer Adsuara C, Hernandez Garfella M, Cervera Taulet E. Early macular toxicity following 2 months of hydroxychloroquine therapy. Archivos de la Sociedad Espanola de Oftalmologia. 2018;93(3):20-21.  https://doi.org/10.1016/j.oftal.2017.12.004
  22. Browning DJ. Pharmacology of Chloroquine and Hydroxychloroquine. Hydroxychloroquine and Chloroquine Retinopathy. In: Hydroxychloroquine and Chloroquine Retinopathy. New York, NY: Springer; 2014;35-63.  https://doi.org/10.1007/978-1-4939-0597-3_2
  23. Ivanina TA, Zueva MV, Lebedeva MN, Bogoslovsky AI, Bunin AJ. Ultrastructural alterations in rat and cat retina and pigment epithelium induced by chloroquine. Graefe’s Archive for Clinical and Experimental Ophthalmology. 1983;220:32-38. 
  24. Marmor MF, Hu J. Effect of disease stage on progression of hydroxychloroquine retinopathy. JAMA Ophthalmology. 2014;132(9):1105-1112.
  25. Kellner S, Weinitz S, Farmand G, Kellner U. Cystoid macular oedema and epiretinal membrane formation during progression of chloroquine retinopathy after drug cessation. British Journal of Ophthalmology. 2014;98(2): 200-206.  https://doi.org/10.1136/bjophthalmol-2013-303897
  26. Chen E, Brown DM, Benz MS, Fish RH, Wong TP, Kim RY, Major JC. Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the «flying saucer» sign). Clinical Ophthalmology. 2010;4:1151‐1158. https://doi.org/10.2147/OPTH.S14257
  27. Kellner U, Agnes BR, Tillack H. Fundus Autofluorescence and mfERG for Early Detection of Retinal Alterations in Patients Using Chloroquine/Hydroxychloroquine. Investigative Ophthalmology and Visual Science. 2006; 47(8):3531-3538. https://doi.org/10.1167/iovs.05-1290
  28. Garrity ST, Jung JY, Zambrowski O, Pichi F, Su D, Arya M, Waheed NK, Duker JS, Chetrit Y, Miserocchi E, Giuffrè C, Kaden TR, Querques G, Souied EH, Freund KB, Sarraf D. Early hydroxychloroquine retinopathy: optical coherence tomography abnormalities preceding Humphrey visual field defects. British Journal of Ophthalmology. 2019;103(11):1600-1604. https://doi.org/10.1136/bjophthalmol-2018-313350
  29. Marmor MF. COVID-19 and Chloroquine/Hydroxychloroquine: is there Ophthalmological Concern? American Journal of Ophthalmology. 2020; 213:3‐4.  https://doi.org/10.1016/j.ajo.2020.03.028
  30. Pandya HK, Robinson M, Mandal N, Shah VA. Hydroxychloroquine retinopathy: A review of imaging. Indian Journal of Ophthalmology. 2015;63(7): 570-574.  https://doi.org/10.4103/0301-4738.167120
  31. Kan E, Yakar K, Demirag MD, Gok M. Macular ganglion cell-inner plexiform layer thickness for detection of early retinal toxicity of hydroxychloroquine. International Ophthalmology. 2018;38(4):1635-1640. https://doi.org/10.1007/s10792-017-0635-y
  32. Pasadhika S, Fishman GA, Choi D, Shahidi M. Selective thinning of the perifoveal inner retina as an early sign of hydroxychloroquine retinal toxicity. Eye (London, England). 2010;24(5):756‐763.  https://doi.org/10.1038/eye.2010.21
  33. Ahn SJ, Ryu SJ, Joung JY, Lee BR. Choroidal Thinning Associated with Hydroxychloroquine Retinopathy. American Journal of Ophthalmology. 2017; 183:56-64.  https://doi.org/10.1016/j.ajo.2017.08.022
  34. Reiner A, Fitzgerald MEC, Del Mar N, Li C. Neural control of choroidal blood flow. Progress in Retinal and Eye Research. 2018;64:96-130.  https://doi.org/10.1016/j.preteyeres.2017.12.001
  35. Bulut M, Akıdan M, Gözkaya O, Erol MK, Cengiz A, Çay HF. Optical coherence tomography angiography for screening of hydroxychloroquine-induced retinal alterations. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2018;256(11):2075-2081. https://doi.org/10.1007/s00417-018-4117-3
  36. Melles RB, Marmor MF. Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology. 2015;122(1):110-116.  https://doi.org/10.1016/j.ophtha.2014.07.018
  37. Yusuf IH, Sharma S, Luqmani R, Downes SM. Hydroxychloroquine retinopathy. Eye (London, England). 2017;31(6):828-845.  https://doi.org/10.1038/eye.2016.298
  38. Querques G, Souied E. eds. Macular Dystrophies. New York, NY: Springer; 2016.
  39. Allam RS, Abd-Elmohsen MN, Khafagy MM, Raafat KA, Sheta SM. Spectral-Domain Optical Coherence Tomography of Preclinical Chloroquine Maculopathy in Egyptian Rheumatoid Arthritis Patients. Journal of Ophthalmology. 2015;292357. https://doi.org/10.1155/2015/292357
  40. Stokkermans TJ, Trichonas G. Chloroquine and Hydroxychloroquine Toxicity. Stat Pearls. Updated June 4, 2019. Accessed 16.04.20.  https://www.ncbi.nlm.nih.gov/books/NBK537086/
  41. van Rijssen TJ, van Dijk EHC, Yzer S, Ohno-Matsui K, Keunen JEE, Schlingemann RO, Sivaprasad S, Querques G, Downes SM, Fauser S, Hoyng CB, Piccolino FC, Chhablani JK, Lai TYY, Lotery AJ, Larsen M, Holz FG, Freund KB, Yannuzzi LA, Boon CJF. Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Progress in Retinal and Eye Research. 2019;73:100770. https://doi.org/10.1016/j.preteyeres.2019.07.003
  42. Noupuu K, Lee W, Zernant J, Tsang SH, Allikmets R. Structural and Genetic Assessment of the ABCA4-Associated Optical Gap Phenotype. Investigative Ophthalmology and Visual Science. 2014;55(11):7217‐7226. https://doi.org/10.1167/iovs.14-14674
  43. Marmor MF. Comparison of screening procedures in hydroxychloroquine toxicity. Archives of Ophthalmology. 2012;130(4):461-469.  https://doi.org/10.1001/archophthalmol.2011.371
  44. Noupuu K, Lee W, Zernant J, Greenstein VC, Tsang S, Allikmets R. Recessive Stargardt disease phenocopying hydroxychloroquine retinopathy. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2016;254(5):865-872.  https://doi.org/10.1007/s00417-015-3142-8
  45. Langwińska-Wośko E, Szulborski K, Zaleska-Żmijewska A, Szaflik J. Electrophysiological testing as a method of cone-rod and cone dystrophy diagnoses and prediction of disease progression. Documenta Ophthalmologica. 2015;130(2):103-109.  https://doi.org/10.1007/s10633-015-9479-9
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.